Preconditioning with β‐hydroxybutyrate attenuates lung ischemia–reperfusion injury by suppressing alveolar macrophage pyroptosis through the SIRT1‐FOXO3 signaling pathway

Abstract

AbstractThe complex pathogenesis of lung ischemia–reperfusion injury (LIRI) was examined in a murine model, focusing on the role of pyroptosis and its exacerbation of lung injury. We specifically examined the levels and cellular localization of pyroptosis within the lung, which revealed alveolar macrophages as the primary site. The inhibition of pyroptosis by VX‐765 reduced the severity of lung injury, underscoring its significant role in LIRI. Furthermore, the therapeutic potential of β‐hydroxybutyrate (β‐OHB) in ameliorating LIRI was examined. Modulation of β‐OHB levels was evaluated by ketone ester supplementation and 3‐hydroxybutyrate dehydrogenase 1 (BDH‐1) gene knockout, along with the manipulation of the SIRT1‐FOXO3 signaling pathway using EX‐527 and pCMV‐SIRT1 plasmid transfection. This revealed that β‐OHB exerts lung‐protective and anti‐pyroptotic effects, which were mediated through the upregulation of SIRT1 and the enhancement of FOXO3 deacetylation, leading to decreased pyroptosis markers and lung injury. In addition, β‐OHB treatment of MH‐S cells in vitro showed a concentration‐dependent improvement in pyroptosis, linking its therapeutic benefits to specific cell mechanisms. Overall, this study highlights the significance of alveolar macrophage pyroptosis in the exacerbation of LIRI and indicates the potential of β‐OHB in mitigating injury by modulating the SIRT1‐FOXO3 signaling pathway.